BNC Korea Co., Ltd. (KOSDAQ:256840)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,265.00
-5.00 (-0.12%)
Apr 25, 2025, 12:39 PM KST
-32.94%
Market Cap 292.05B
Revenue (ttm) 89.23B
Net Income (ttm) 13.31B
Shares Out 68.39M
EPS (ttm) 198.48
PE Ratio 21.51
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 133,468
Average Volume 177,993
Open 4,345.00
Previous Close 4,270.00
Day's Range 4,220.00 - 4,345.00
52-Week Range 3,475.00 - 7,200.00
Beta 1.10
RSI 64.99
Earnings Date May 14, 2025

About BNC Korea

BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj., temporary reduce glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity; Juvegel, temporary reduce nasolabial folds in adults; Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia; HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, CUTEGEL-M,... [Read more]

Sector Healthcare
Founded 2007
Employees 213
Stock Exchange KOSDAQ
Ticker Symbol 256840
Full Company Profile

Financial Performance

In 2024, BNC Korea's revenue was 89.23 billion, an increase of 10.16% compared to the previous year's 81.00 billion. Earnings were 13.31 billion, a decrease of -48.19%.

Financial Statements

News

There is no news available yet.